Huadong Medicine Co Ltd 2021 AR2
The report outlines Huadong Medicine Co., Ltd.'s business performance, strategic transformation, and environmental initiatives for the fiscal year 2021. The company advanced its R&D ecosystem in endocrinology, oncology, and autoimmunity, while expanding its aesthetic medicine and industrial microbiology sectors. Environmentally, the company implemented energy-saving and carbon reduction projects across its subsidiaries, significantly reducing power, steam, and water consumption. Additionally, the report highlights the company's corporate governance practices, social responsibility efforts, and commitment to sustainable development.
Company: Huadong Medicine Co Ltd
Sector: Health Care
Country: China
Year: 2021
Type: AR2
Pages: 195
Huadong Medicine Co Ltd
Annual Report
The report outlines Huadong Medicine Co., Ltd.'s business performance, strategic transformation, and environmental initiatives for the fiscal year 2021. The company advanced its R&D ecosystem in endocrinology, oncology, and autoimmunity, while expanding its aesthetic medicine and industrial microbiology sectors. Environmentally, the company implemented energy-saving and carbon reduction projects across its subsidiaries, significantly reducing power, steam, and water consumption. Additionally, the report highlights the company's corporate governance practices, social responsibility efforts, and commitment to sustainable development.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Published
Apr 1, 2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees